KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Share-based Compensation (2017 - 2025)

Teva Pharmaceutical Industries' Share-based Compensation history spans 9 years, with the latest figure at $51.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 50.0% year-over-year to $51.0 million, compared with a TTM value of $157.0 million through Dec 2025, up 27.64%, and an annual FY2025 reading of $157.0 million, up 27.64% over the prior year.
  • Share-based Compensation for Q4 2025 was $51.0 million at Teva Pharmaceutical Industries, up from $34.0 million in the prior quarter.
  • The five-year high for Share-based Compensation was $51.0 million in Q4 2025, with the low at $24.0 million in Q1 2022.
  • Average Share-based Compensation over 5 years is $32.2 million, with a median of $31.5 million recorded in 2021.
  • Year-over-year, Share-based Compensation decreased 23.08% in 2023 and then soared 50.0% in 2025.
  • Tracing TEVA's Share-based Compensation over 5 years: stood at $33.0 million in 2021, then grew by 9.09% to $36.0 million in 2022, then dropped by 22.22% to $28.0 million in 2023, then increased by 21.43% to $34.0 million in 2024, then soared by 50.0% to $51.0 million in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Share-based Compensation are $51.0 million (Q4 2025), $34.0 million (Q3 2025), and $38.0 million (Q2 2025).